Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Rhea-AI Summary

Alpha Cognition Inc. (NASDAQ: ACOG) has achieved significant milestones in 2024, including FDA approval for its Alzheimer's therapy ZUNVEYL (benzgalantamine), a successful $4.5M financing round, and NASDAQ listing preparations. The company is positioned to launch ZUNVEYL in Q1 2025, with sales force and commercial production already in place.

ZUNVEYL targets the long-term care (LTC) market, which represents a $2 billion addressable market and 36% of Alzheimer's prescriptions. The drug's prodrug mechanism improves patient outcomes by reducing common side effects like nausea and insomnia. Additionally, Alpha Cognition has secured a $44M licensing agreement with China Medical Systems Holdings.

Positive

• FDA approval received for ZUNVEYL Alzheimer's therapy
• Successful $4.5M financing round completed
• $44M licensing deal secured with China Medical Systems Holdings
• Ready for commercial launch in Q1 2025 with sales force in place
• Targeting $2B addressable market in long-term care sector

Negative

• None.

Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition Inc. reported significant progress in 2024 so far, marked by key financial and corporate milestones. Alpha Cognition received approval for its flagship Alzheimer's therapy ZUNVEYL (benzgalantamine), successfully raised $4.5M in financing, and completed the necessary preparations for listing on the NASDAQ exchange. These initiatives have positioned the Company to launch ZUNVEYL in 1Q25, with an in place sales force and commercial production already underway.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Alpha Cognition is set to launch ZUNVEYL in 1Q25, targeting the long-term care (LTC) market, a $2 billion addressable market representing 36% of Alzheimer's prescriptions.
• ZUNVEYL's prodrug mechanism bypasses GI absorption, significantly reducing common side effects like nausea and insomnia, leading to better patient adherence and improved cognitive benefits.
• Alpha Cognition has secured a $44M licensing deal with China Medical Systems Holdings.

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238961

FAQ

When will Alpha Cognition (ACOG) launch ZUNVEYL in the market?

Alpha Cognition plans to launch ZUNVEYL in the first quarter of 2025, with sales force and commercial production already in place.

What is the market size for ZUNVEYL (ACOG) in the long-term care sector?

ZUNVEYL targets a $2 billion addressable market in the long-term care (LTC) sector, which represents 36% of Alzheimer's prescriptions.

What are the advantages of ZUNVEYL's prodrug mechanism for Alzheimer's patients?

ZUNVEYL's prodrug mechanism bypasses GI absorption, significantly reducing common side effects like nausea and insomnia, leading to better patient adherence and improved cognitive benefits.

How much is Alpha Cognition's (ACOG) licensing deal with China Medical Systems worth?

Alpha Cognition has secured a $44M licensing deal with China Medical Systems Holdings.

How much funding did Alpha Cognition (ACOG) raise in its recent financing round?

Alpha Cognition successfully raised $4.5M in its recent financing round.